Romanian journal of ophthalmology · 2025
A Case Series of Serious Adverse Events Following Anti-VEGF Intravitreal Injections.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Muşat Andreea Alexandra Mihaela, Zamfiroiu-Avidis Nicoleta, Ştefan Cornel, Andreea Schmitzer, Muşat Gabriela, Udrea Gabriela, Popescu Ioana Stella, Muşat Ovidiu
Аннотация
PURPOSE: To highlight serious adverse effects regarding intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy, which is widely used for the treatment of retinal diseases, including two cases of post-injection endophthalmitis, one of which was complicated by rhegmatogenous retinal detachment, and one case of secondary cataract following a potentially unnecessary injection.
METHODS: A retrospective analysis of three cases that developed complications after intravitreal anti-VEGF therapy.
RESULTS: All cases resulted in a decline in best corrected visual acuity (BCVA) that required additional surgical procedures.
DISCUSSION: While intravitreal anti-VEGF therapy has become the standard in the treatment of various retinal pathologies, it is not without risks. This case series presents significant adverse outcomes, emphasizing the potential for severe anatomical and functional consequences. As the global volume of anti-VEGF intravitreal injections increases, so must our commitment to patient safety, precision in diagnosis, and ethical decision making.
CONCLUSION: Although generally safe and commonly used in clinical practice, physicians must be aware of the risks of anti-VEGF therapy and must remain vigilant regarding patient selection and risk-benefit considerations.
METHODS: A retrospective analysis of three cases that developed complications after intravitreal anti-VEGF therapy.
RESULTS: All cases resulted in a decline in best corrected visual acuity (BCVA) that required additional surgical procedures.
DISCUSSION: While intravitreal anti-VEGF therapy has become the standard in the treatment of various retinal pathologies, it is not without risks. This case series presents significant adverse outcomes, emphasizing the potential for severe anatomical and functional consequences. As the global volume of anti-VEGF intravitreal injections increases, so must our commitment to patient safety, precision in diagnosis, and ethical decision making.
CONCLUSION: Although generally safe and commonly used in clinical practice, physicians must be aware of the risks of anti-VEGF therapy and must remain vigilant regarding patient selection and risk-benefit considerations.